// App-Quantinova.ai

ABS114 : FOLLOW‐UP ON A NOVEL ADENO ASSOCIATED VIRUS (AAV) GENE THERAPY (FLT180A) ACHIEVING NORMAL FIX ACTIVITY LEVELS IN SEVERE HEMOPHILIA B (HB) PATIENTS (B‐AMAZE STUDY).

Researchers

Presenter

  • P. Chowdary

Principal Investigators

  • S. Shapiro

  • M. Makris

  • G. Evans

  • S. Boyce

  • K. Talks

  • G. Dolan

  • U. Reiss

  • M. Phillips

  • A. Riddell

  • M. R. Peralta

  • M. Quaye

  • T. Tuddenham

  • A. Smith

  • A. Long

  • J. Krop

  • A. Nathwani

Medical Centers

  • Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK

  • University College London, London, UK

  • Oxford Haemophilia Centre, Oxford

  • CIMA, University of Sheffield, Sheffield, UK

  • Kent and Canterbury Hospital, Canterbury

  • University of Southampton, Southampton, UK

  • Newcastle Haemophilia Comprehensive Care Centre, Newcastle

  • St Thomas’ and Guy’s Hospital, London, United Kingdom

  • St Jude Childrens Research Hospital, Memphis, TN, United States

  • Freeline Therapeutics, Stevenage, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Adaptive

  • Multicenteric

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved